By The Uromigos - Last Updated: September 11, 2022
Axel Bex summarizes the RCC studies that were presented at ESMO 2022, including potential toxicity of ipilimumab/nivolumab, pembrolizumab response rates, and single-agent atezolizumab versus placebo.